Intra-tumoral Heterogeneity of KRAS and BRAF Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing

Intra-tumoral Heterogeneity of KRAS and BRAF Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing

KRAS mutation status is established as a predictive biomarker of benefit from anti-EGFr therapies. Mutations are normally assessed using DNA extracted from one formalin-fixed, paraffin-embedded (FFPE) tumor block. We assessed heterogeneity of KRAS and BRAF mutation status intra-tumorally (multiple b...

Full description

Saved in:
Bibliographic Details
Main Authors: Susan D. Richman, Philip Chambers, Matthew T. Seymour, Catherine Daly, Sophie Grant, Gemma Hemmings, Philip Quirke
Format: Article
Language:English
Published: Wiley 2011-01-01
Series:Analytical Cellular Pathology
Online Access:http://dx.doi.org/10.3233/ACP-2011-0005
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items